Key result
Ivabradine administration in cardiogenic shock patients on VA-ECMO reduced heart rate by 20.83 bpm and improved native stroke volume.
Why the study?
Ivabradine was safe in small non-randomized series of patients with cardiogenic shock without mechanical circulatory support, but its use in patients on mechanical circulatory support required evaluation.
Does ivabradine improve haemodynamics and reduce heart rate in patients with cardiogenic shock on VA-ECMO?
Cohort
Does ivabradine improve haemodynamics and reduce heart rate in patients with cardiogenic shock on VA-ECMO?
In patients with cardiogenic shock on VA-ECMO, ivabradine significantly reduced heart rate and improved native stroke volume, facilitating the weaning of ECMO support and vasopressors.
Answers are grounded in this paper and cite their sources.
Suggests ivabradine may improve hemodynamics during VA-ECMO; leaves open whether this.
AIMS: Cardiogenic shock (CS) is a life-threatening condition due to primary cardiac dysfunction. First-line therapy involves drug administration (including inotropes and/or vasopressors) up to mechanical circulatory support. Tachycardia is a frequent compensatory mechanism in response to hypotension and low cardiac output or a side effect related to inotropic drugs. Ivabradine selectively acts on the IKf channel in the sinoatrial node to reduce sinus heart rate without affecting inotropism. Its use, in small non-randomized series of patients with CS without mechanical circulatory support, was safe and well tolerated. METHODS AND RESULTS: We present the use of ivabradine in six patients with CS undertaking veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and a matched cohort of selected patients with similar features who did not receive ivabradine. Data regarding haemodynamic and echocardiographic monitoring, oxygenation, renal function, mechanical circulatory support, inotropes, and vasopressors doses were collected before (t0), at 12 (t1), 24 (t2), and 48 (t3) h after ivabradine administration. Ivabradine administration led to a significant heart rate reduction of 20.83 [95% confidence interval (CI) -27.2 to -14.4] b.p.m. (<0.01). Echo-derived left ventricular native stroke volume (SV) significantly increased by +7.83 (95% CI 4.74-10.93) mL (P < 0.001) with a parallel reduction of VA-ECMO support [-170 (95% CI -225.05 to -114.95)]. Noradrenaline was down-titrated over the observation period in all patients (P = 0.016). CONCLUSION: A significant reduction in heart rate was observed after ivabradine administration. This was associated with a native ventricular SV improvement allowing the reduction of extracorporeal flow support and vasopressors administration.
No takes yet. Share an insight, caveat, or question.
Colombo et al. (2022) conducted a cohort in Cardiogenic shock on mechanical circulatory support. Ivabradine vs. Matched cohort not receiving ivabradine was evaluated on Heart rate reduction (MD -20.83, 95% CI -27.2 to -14.4, p=<0.01). Ivabradine administration in cardiogenic shock patients on VA-ECMO reduced heart rate by 20.83 bpm and improved native stroke volume.
Synapse has enriched 10 related papers. Consider them for comparative context: